Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06032117 · ClinicalTrials.gov registry record

Characterizing Protein Biomarkers of Post-infection Irritable Bowel Syndrome

A clinical trial, sponsored by University of Nevada, Reno.

Completed
Registry status
81
Enrollment target

NCT06032117 is a clinical trial that has completed, run by University of Nevada, Reno. The registered enrollment target is 81 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06032117 has completed, sponsored by University of Nevada, Reno.

COMPLETED
Registry status
81 participants
Enrollment target

Study Summary

The investigators will characterize and compare protein signatures between groups with and without post-infection irritable bowel syndrome (PI-IBS). From previous Healthy Nevada Project (HNP) participants, at least 60 patients with PI-IBS and 60 healthy controls will undergo additional proteomics testing, age, sex and race/ethnicity-matched healthy. The investigators will use proteomic testing to detect, quantify and characterize serum protein biomarkers and protein signatures, and compare biomarkers and signatures between the patient groups of interest. Serum samples will be analyzed by the Nevada Proteomics Center. Samples will first undergo protein digestion, then peptides are separated using liquid chromatography (LC), mass spectral analysis is performed using an Orbitrap Eclipse mass spectrometer (Thermo Scientific, San Jose, CA) using data-independent acquisition (DIA). Library generation and data analysis will be performed using Spectronaut software (Biognosys, Schlieren, Switzerland). The Nevada Proteomics Center and Bioinformatics Center will be engaged during the data analyses comparing biomarkers and signatures between the patient groups of interest. This research aim has the potential to add to our understanding of the underlying mechanisms of PI-IBS and to create reliable differentiating protein biomarkers to better diagnose PI-IBS.

Trial Details

FieldValue
Enrollment Target 81 participants
Start Date 2024-04-11
Est. Completion 2024-12-30

Sponsor

University of Nevada, Reno

23 total trials

What the Registry Record Tells You About NCT06032117

The ClinicalTrials.gov registry entry for NCT06032117 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Nevada, Reno, which has 23 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT06032117 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT06032117 about?

NCT06032117 is a clinical study titled "Characterizing Protein Biomarkers of Post-infection Irritable Bowel Syndrome". The investigators will characterize and compare protein signatures between groups with and without post-infection irritable bowel syndrome (PI-IBS). From previous Healthy Nevada Project (HNP) participants, at least 60 patients with PI-IBS and 60 healthy controls will undergo additional proteomics te...

What is the current status of trial NCT06032117?

This trial is currently completed. The enrollment target is 81 participants. The study started on 2024-04-11. Estimated completion is 2024-12-30.

Who is sponsoring clinical trial NCT06032117?

This trial is sponsored by University of Nevada, Reno, which has 23 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.